StreetInsider.com News Articles

MiniMed Group (MMED) PT Raised to $27 at StoneX on Conservative Revenue Guide

Wed, 02 Sep 2026 09:32:07 -0400

StoneX analyst Bruce Jackson raised the price target on MiniMed Group (NASDAQ: MMED) to $27.00 (from $20.00) while maintaining a Buy rating.

The analyst commented, "MiniMed reported better than expected FQ1 results, raised full-year organic revenue guidance and maintained its Adjusted EBITDA margin target of 16%. Revenue of $843 million (up 17%, 16% cc) was better than consensus of $827 million and our estimate of $829 million. Excluding the impact of an extra week in the quarter due to the 52/53 week fiscal calendar, total organic growth was still in the low-double-digit range. Highlights included commercial execution in the United States

MiniMed Group (MMED) PT Raised to $27 at StoneX on Conservative Revenue Guide

Wed, 02 Sep 2026 09:32:07 -0400

StoneX analyst Bruce Jackson raised the price target on MiniMed Group (NASDAQ: MMED) to $27.00 (from $20.00) while maintaining a Buy rating.

MiniMed Group (MMED) PT Raised to $25 at Deutsche Bank

Wed, 02 Sep 2026 08:12:26 -0400

Deutsche Bank analyst Pito raised the price target on MiniMed Group (NASDAQ: MMED) to $25.00 (from $20.00) while maintaining a Buy rating.

MiniMed Group (MMED) PT Raised to $28 at UBS

Wed, 02 Sep 2026 08:09:37 -0400

(Updated - September 2, 2026 8:09 AM EDT)

UBS analyst Patrick Wood raised the price target on MiniMed Group (NASDAQ: MMED) to $28.00 (from $25.00) while maintaining a Buy rating.

The analyst commented, "MMED shares closed up +LDD% after the company delivered a solid 1Q27, with total revenue of $843mn ($240mn US / $603mn OUS) coming in ~2% ahead of the Street at $828mn. Importantly, NPS grew +20% in the US (+7% overall) supported by the initial rollout of MiniMed Flex which began shipping in late June and Instinct strength in western Europe, while CGM attachment rates remain strong at 69% (+500bps y/y).

MiniMed Group (MMED) PT Raised to $28 at UBS

Wed, 02 Sep 2026 08:09:37 -0400

(Updated - September 2, 2026 8:09 AM EDT)

UBS analyst Patrick Wood raised the price target on MiniMed Group (NASDAQ: MMED) to $28.00 (from $25.00) while maintaining a Buy rating.

MiniMed Group (MMED) PT Raised to $26 at Mizuho

Wed, 02 Sep 2026 06:48:03 -0400

Mizuho analyst Anthony Petrone raised the price target on MiniMed Group (NASDAQ: MMED) to $26.00 (from $21.00) while maintaining a Outperform rating.

MiniMed Group (MMED) PT Raised to $28 at BofA Securities

Wed, 02 Sep 2026 05:17:19 -0400

BofA Securities analyst Travis Steed raised the price target on MiniMed Group (NASDAQ: MMED) to $28.00 (from $24.00) while maintaining a Buy rating.

The analyst comments "MMED delivered a solid FQ1 with WW revs 2% above Street and US grew HSD% and OUS low DD% organically even after adjusting for extra selling week (4-6% impact in FQ1). MMED announced submission of Fit to FDA (vs prior Fall target) and now expects a Summer 2027 launch (reiterated 20k manufacturing capacity at launch). Flex also received CE Mark ahead of schedule (was expected before YE CY26) and will launch in November. We continue

MiniMed Group (MMED) PT Raised to $28 at BofA Securities

Wed, 02 Sep 2026 05:17:19 -0400

BofA Securities analyst Travis Steed raised the price target on MiniMed Group (NASDAQ: MMED) to $28.00 (from $24.00) while maintaining a Buy rating.

MiniMed Group (MMED) PT Raised to $26 at Wells Fargo

Wed, 02 Sep 2026 05:15:20 -0400

Wells Fargo analyst Larry Biegelsen raised the price target on MiniMed Group (NASDAQ: MMED) to $26.00 (from $22.00) while maintaining a Overweight rating.

The analyst comments "Q1 sales beat on OUS; US growth accelerated. Revenue of $843M (+15.8% org) beat our $833M/Street's $827M. OUS of $603M (+16.9% org) beat our $590M by $13M, while US of $240M (+13.1%) was ~$3M below our $243M. Excluding the extra week (~4-6% benefit to Q1, or $36M at the midpoint), WW and OUS growth were LDD%, while US was HSD%. With only five weeks of Flex shipments, we believe US growth exited the quarter above

MiniMed Group (MMED) PT Raised to $26 at Wells Fargo

Wed, 02 Sep 2026 05:15:20 -0400

Wells Fargo analyst Larry Biegelsen raised the price target on MiniMed Group (NASDAQ: MMED) to $26.00 (from $22.00) while maintaining a Overweight rating.

MiniMed Group (MMED) PT Raised to $26 at Citi

Wed, 02 Sep 2026 05:04:43 -0400

Citi analyst Joanna Wuensch raised the price target on MiniMed Group (NASDAQ: MMED) to $26.00 (from $23.00) while maintaining a Buy rating.

MiniMed Group (MMED) PT Raised to $28 at BTIG

Tue, 01 Sep 2026 12:12:44 -0400

BTIG analyst Marie Thibault raised the price target on MiniMed Group (NASDAQ: MMED) to $28.00 (from $25.00) while maintaining a Buy rating.

The analyst comments "MiniMed keeps hitting its product pipeline goals ahead of schedule, setting up a catalyst-rich FY2027. MMED reported F1Q revenue of $843M (+15.8% y/y org., +16.6% y/y rep.), a ~$16M beat on consensus ($826.8M), including an approximate 4-6% benefit from the extra selling week. Excluding the extra week, the company generated low-double digit organic growth. Both U.S. and OUS revenue exceeded expectations, with U.S. $240M vs. cons. $236.0M and OUS $603M vs. cons. $588.1M. U.S. sales growth

MiniMed Group (MMED) PT Raised to $28 at BTIG

Tue, 01 Sep 2026 12:12:44 -0400

BTIG analyst Marie Thibault raised the price target on MiniMed Group (NASDAQ: MMED) to $28.00 (from $25.00) while maintaining a Buy rating.

MiniMed Group (MMED) Reiterated at Buy by StoneX Ahead of Q1 Earnings

Tue, 01 Sep 2026 08:50:10 -0400

StoneX analyst Bruce Jackson reiterated a Buy rating and $20.00 price target on MiniMed Group (NASDAQ: MMED).

The analyst commented, "MiniMed is scheduled to release FQ1 results tomorrow BMO. We are forecasting FQ1 2027 Adjusted EBITDA of $117 million on revenue of $829 million, which includes FX impact of approximately +0.5%. Consensus calls for $117 million and $827 million, respectively. We anticipate a strong FQ1 due to a combination of pent-up demand as users delayed purchasing a new pump in anticipation of the Flex. Management has guided to organic revenue growth of approximately 10% for FY 2027 with Adjusted EBITDA margins

MiniMed to Participate in Upcoming Investor Conferences

Tue, 25 Aug 2026 09:03:00 -0400

NORTHRIDGE, Calif., Aug. 25, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that management will participate in fireside chats at the following investor conferences:

MiniMed to Participate in Upcoming Investor Conferences

Tue, 25 Aug 2026 09:03:00 -0400

Form ARS MiniMed Group, Inc. For: Apr 24

Fri, 21 Aug 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260821/26961705.html

Form DEFA14A MiniMed Group, Inc.

Fri, 21 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260821/26961643.html

Form DEF 14A MiniMed Group, Inc. For: Oct 09

Fri, 21 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260821/26961606.html

MiniMed ships its Flex pump with Abbott's Instinct sensor in the U.S.

Mon, 17 Aug 2026 09:04:46 -0400

MiniMed (Nasdaq: MMED) announced that its MiniMed Flex™ insulin pump system is now commercially shipping in the U.S. paired with the Instinct sensor, made by Abbott, which the company claims is the world's smallest patient-applied continuous glucose sensor.

The Instinct sensor supports up to 15 days of wear per session. The MiniMed Flex™ is described by the company as its smallest and only app-controlled automated insulin delivery system. It holds up to 300 units of insulin and is compatible with the Extended™ infusion set, which can be worn for up to seven days.

The system is powered by MiniMed's SmartGuard™ algorithm, which

MiniMed's Smallest App-Controlled Insulin Pump Now Shipping with the World's Smallest Sensor

Mon, 17 Aug 2026 09:04:00 -0400